| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9005647 | Clinical Therapeutics | 2005 | 22 Pages |
Abstract
For patients with NSCLC in whom1026 more than 1 or 2 previous chemotherapeutic regimens have failed, erlotinib is an effective therapy with significant overall survival benefits. The use of erlotinib as first-line therapy in combination with platinum-based chemotherapeutic regimens, however, has failed to demonstrate efficacy in the treatment of NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
PharmD Smith,